Halozyme CEO Helen Torley
March 29, 2022 02:07 PM EDTUpdated March 31, 10:25 AM
Deals

Roche's Chugai lines up a $185M deal to switch drug can­di­date to sub­cu­ta­neous for­mu­la­tion

John Carroll

Editor & Founder

Back in the spring of 2020, J&J and its part­ner on the big mul­ti­ple myelo­ma drug Darza­lex an­nounced a big im­prove­ment for the pro­gram af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Biotech VC firm out­lines plans for $100M fund

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times